Full safety profile Multiple species 96-well Service outputs aProximate TM Evaluation of KIM-1, NGAL, and clusterin, three FDA-approved biomarkers of kidney toxicity Cell viability: ATP, LDH, and TEER measurements Assays Kidney toxicity assays Assessment of renal drug safety Models aProximate TM kidney proximal tubule cells (from human, mouse, rat, and dog) Timeline 2-3 months How can Newcells kidney tissue models be used to assess renal toxicity
Mechanisms of Action-Mediated DDIs Furthermore, assessing DDIs for GLP-1 RAs and a dual GLP-1/GIP RA requires additional considerations, including the possible occurrence of DDIs mediated by mechanisms of action that remain poorly understood (Figure 3)
Luger, Are melanocortin peptides future therapeutics for cutaneous wound healing?, Wiley, Feb
Development of collagen blends with added functional ingredients for multi-benefit solutions